For more than half a century, patients with Non-Valvular Atrial Fibrillation (NVAF) have been using vitamin K antagonist (Warfarin) to prevent stroke and thromboembolism. Warfarin has proved to be effective, however, it comes with its own baggage of side effects. The use of warfarin is limited due to risk of […]
There is no doubt that VKAs (Warfarin) have been used since over 50 years for the management of stroke prevention in Non-Valvular Atrial Fibrillation and Venous Thromboembolism. However, the emergence of non-vitamin K oral anticoagulants such as Pradaxa, Xarelto, Eliquis and Lixiana have changed the landscape of thromboprophylaxis.